PUBLIC COMPANY
save$FOLDAMICUS THERAPEUTICS, INC.
$FOLD14.490.00%Princeton, NJ, USupdated 3mo ago
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
community read0 votes
pipeline
4
marketed
3
phase 3
1
catalysts ytd
3
approvals ytd
0
recalls ytd
0
Pipeline(4)
pipeline depth4 products
1Phase 33Marketed
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- —Expanded Access for ATB200/AT2221 for the Treatment of IOPD
- —A Study of Patients With Fabry Disease (US Specific)
- phase3A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
- phase3A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease
- —A Global Prospective Observational Registry of Patients With Pompe Disease
- phase3A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)
- phase3Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease
- —A Study to Describe the Experience of Both Patients and Their Clinicians in the Treatment of Fabry Disease With Enzyme Replacement Therapy.
🐶 Hiring Signal
News
- AI bio startup Boltz raises $110M Series ALONDON — Less than a year after launching from stealth with $28 million, the AI bio startup Boltz has raised a $110 million Series A round, its leaders exclusively told Endpoints News. The ...endpoints · 4h ago
- AstraZeneca, Calidi, Tempest make significant workforce cutsFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 1d ago
- Ira Mellman wants Parker Institute to restore cancer immunotherapyWhile the whole world was applauding Revolution Medicines' new cancer drug, all Ira Mellman felt was disappointment and frustration. The pill, daraxonrasib, kept patients with advanced pancreatic c…endpoints · 6d ago
- FDA orders class-wide GLP-1 label update to include potential risk for rare eye diseaseTwelve marketed drugs, including Eli Lilly’s and Novo’s weight loss mega-blockbusters, will require a label change under the new FDA update.biospace · 8d ago
- Sarepta’s new CEO confident in clinical execution as DMD competitors close inSarepta Therapeutics’ newly minted CEO Michael Severino laid out his path to returning the muscular dystrophy therapy maker to the forefront of the rapidly expanding market.biospace · 12d ago
- Sun Pharma stops eye-care drug production at Indian plant amid quality issuesThe cessation of manufacturing activities follows a Sun Pharma recall and reports that regulators found fault with the company’s quality system.biospace · 15d ago
- Opinion: What a mother’s 1834 letter about measles tells us about MAHAAn 1834 letter about a measles outbreak sheds light on today’s anti-vaccine movement, writes a medical historian.stat · 19d ago
- Novartis faces $1.9B hit from Avidity fail but maintains confidence in $12B buyNovartis remains "very happy" with its $12 billion acquisition of Avidity Biosciences, despite a Phase 3 disappointment for the antibody-oligonucleotide conjugate del-desiran.biospace · 22d ago
- Moderna, Merck shares fall on eagerly anticipated cancer vaccine resultsA combination of the shot and the immunotherapy Keytruda cut the risk of relapse or death by 42% in a landmark melanoma study that met Wall Street expectations but triggered a “sell-the-news reacti…biopharma_dive · 26d ago
- Opinion: Replication is necessary even if scientists do everything right“Committing a Type 1 error does not reflect poorly on the quality of the science done,” writes Mark Louie F. Ramosstat · 28d ago
Data sources
last refreshed 46m ago
Found something off?
comments(0)
5-min edit window · permanent after that